The United States Court of Appeals for the Federal Circuit recently upheld the validity of several patents held by Exelixis, Inc. against MSN Laboratories Private Ltd. This ruling, decided on August 31, 2026, affects the pharmaceutical industry, particularly in the realm of cancer treatments. The decision is significant because it reinforces the protection of innovative drugs and could influence future patent disputes in the sector.
In the case identified as Exelixis, Inc. v. MSN Laboratories Private Ltd., docket number 25-1236, the court addressed the validity of United States Patent Nos. 11,091,439, 11,091,440, 11,098,015, and 11,298,349. These patents pertain to cabozantinib (L)-malate, a compound used in the treatment of various cancers, including kidney and liver cancer. The court's ruling is crucial for Exelixis as it aims to maintain its market position against generic competitors.
The dispute began when MSN Laboratories submitted an Abbreviated New Drug Application (ANDA) seeking FDA approval for a generic version of cabozantinib. Exelixis responded by filing lawsuits alleging that MSN infringed on its patents. The case was consolidated into two lawsuits in the District Court for Delaware, where the judge ruled in favor of Exelixis, prompting MSN to appeal the decision.
Exelixis holds the New Drug Application for Cabometyx®, which contains cabozantinib (L)-malate. The company initially filed for patents on this drug in the early 2000s after conducting research to identify effective forms of the compound. The patents in question describe crystalline forms of cabozantinib (L)-malate, which are believed to have superior properties for pharmaceutical development.
During the trial, MSN acknowledged that it infringed on Exelixis' patents but argued that the patents were invalid due to a lack of adequate written description as required by 35 U.S.C. § 112(a). The district court, however, found that Exelixis had provided sufficient written description support for the asserted claims of the Malate Salt Patents. The court noted that the specification disclosed structural features common to the claimed genus of crystalline cabozantinib (L)-malate salts.
The Federal Circuit, with Circuit Judge Stoll presiding, affirmed the district court's findings. The court stated, "The key feature of the genus is the chemical formula and structure of crystalline cabozantinib (L)-malate, as all crystalline cabozantinib malate share the same chemical name and formula." This affirmation underscores the importance of a clear and detailed patent specification in establishing the validity of a patent claim.
Additionally, the court dismissed MSN's appeal regarding the asserted claim of the ’349 patent, which relates to processes for preparing cabozantinib compositions that are free from certain impurities. The district court had previously ruled that MSN's product did not infringe this claim, and the Federal Circuit found that MSN's arguments were moot.
The impact of this ruling is significant for the pharmaceutical industry. By upholding the validity of Exelixis' patents, the court has reinforced the protection of innovative drugs, which may deter generic companies from entering the market with similar products. This decision also sets a precedent for how written descriptions in patent applications are evaluated, potentially influencing future patent litigation.
Looking ahead, the ruling may lead to further legal battles as generic manufacturers seek to challenge other patents held by Exelixis or similar companies. The decision also opens the door for Exelixis to continue its market exclusivity until the patents expire, which could be as late as 2030 for some of the claims involved.
As for the possibility of appeal, the Federal Circuit's decision is generally considered final unless the Supreme Court decides to hear the case. Currently, there are no related cases pending that directly connect to this decision.